跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT03480230
NCT03480230Unknown2 期

Phase II Trial of Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

Arafat Tfayli5 个研究点 分布在 2 个国家目标入组 60 人开始时间: 2018年6月26日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
60
试验地点
5
主要终点
Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to assess the response rate to neoadjuvant Compound 121564 plus platinum doublet chemotherapy in patients with early stage non-small cell lung cancer.

详细描述

Open-label, single-arm multi-center phase II trial of neoadjuvant Compound 121564 plus platinum doublet chemotherapy conducted among patients with early stage (IB, II, IIIA) non-small cell lung cancer.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Males and females aged ≥ 18 years.
  • •Histologically confirmed NSCLC (squamous and non-squamous).
  • •High-risk stage IB (tumor ≥ 4 cm in size, or grade 3, or with visceral pleura involvement), II or IIIA disease.
  • •Have biopsy tissue available (fresh and archived) for PD-L1 and correlative studies testing prior to therapy.
  • •Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤
  • •Have a life expectancy of ≥ 6 months. 7) No previous systemic anticancer therapy or surgical resection for his or her NSCLC. 8) Subject has voluntarily agreed to participate by giving written informed consent for the trial. 9) Subject must be willing and able to comply with scheduled visits, treatment schedule and laboratory testing. 10) Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to receiving the first dose of study medication. 11) Females should not be breastfeeding. 12) Female subjects of childbearing potential as well as males sexually active with women of childbearing potential must be willing to use an adequate method of contraception. 13) Have pulmonary and cardiac function testing deemed adequate for thoracic surgical intervention. 14) Have adequate organ function by meeting the following:
  • •Absolute neutrophil count (ANC) ≥1,500/mcL.
  • •Platelets ≥100,000/mcL.
  • •Hemoglobin ≥9 g/dL.
  • •Serum creatinine ≤1.5 X upper limit of normal (ULN) OR calculated creatinine clearance (CrCl) (GFR can also be used in place of creatinine or CrCl) ≥60 mL/min for subjects with creatinine levels > 1.5 X institutional ULN.
  • •Serum total bilirubin ≤ ULN.
  • •AST (SGOT) and ALT (SGPT) ≤ 1.5 X ULN.
  • •Alkaline phosphatase ≤ 2.5 X ULN.
  • •International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless the subject is receiving anticoagulant therapy.
  • •Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless the subject is receiving anticoagulant therapy.

排除标准

  • •Subject deemed unfit for surgery (by pulmonary or cardiac assessment).
  • •Subject with known autoimmune disease that has required systemic therapy in the last 2 years.
  • •Prior organ transplantation including allogenic stem-cell transplantation.
  • •Clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
  • •Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
  • •Subject on immunosuppressive therapy or corticosteroids within 14 days prior to starting study drugs.
  • •Subject with interstitial lung disease that is symptomatic or history of pneumonitis that required oral or systemic glucocorticoids to manage.
  • •Subject must have recovered from the effects of major surgery or significant trauma at least 14 days prior to therapy.
  • •Subject with previous malignancies are excluded unless complete remission was achieved at least 2 years prior to therapy.
  • •Other active malignancy requiring concurrent intervention.
  • •Subject with active infection requiring systemic therapy.
  • •Subject with known history of testing positive for human immunodeficiency virus (HIV) or known to have acquired immunodeficiency syndrome (AIDS).
  • •Subject has known active hepatitis B or C.
  • •Vaccination within 4 weeks of the first dose of Compound 121564 and while on trials is prohibited except for administration of inactivated vaccines.
  • •Subject is pregnant or breastfeeding.
  • •Subject has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • •Subject previously had a severe hypersensitivity reaction to any of the study drugs.
  • •Subject is currently participating and receiving study therapy from another clinical trial.
  • •Subject had prior treatment with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms.
  • •Patient who is not willing to sign the consent form.
  • •Legal incapacity or limited legal capacity patients receiving other oncology specific medication not authorized in the protocol.

研究组 & 干预措施

Treatment arm

Experimental
  1. Non-squamous histology:
  • Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses.
  • Compound 565994 500 mg/m2 administered over 10 minutes, and
  • Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour.
  • Compound 565994 and platinum are to be given on day 1 of every 3-week cycle for 3 cycles.
  1. Squamous histology:
  • Compound 121564 10 mg/Kg administered over 60 minutes every 2 weeks for 4 doses.
  • Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour on day 1 of every cycle.
  • Compound 343782 1,000 mg/m2 administered over 30 minutes on days 1 and 8 of each cycle.
  • Platinum and Compound 343782 will be given for 3 cycles.

干预措施: Compound 121564 (Drug)

结局指标

主要结局

Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria

时间窗: At week 9

To assess the overall response rate (ORR) of patients receiving neoadjuvant Compound 121564 plus platinum doublet chemotherapy based on RECIST 1.1 criteria

次要结局

  • Overall Survival (OS)(At 1, 2 and 3 years)
  • Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria in enrolled squamous vs. non-squamous lung cancer patients(At week 9)
  • Progression-Free Survival (PFS) in enrolled squamous vs. non-squamous lung cancer patients(At 1, 2 and 3 years)
  • Overall Survival (OS) in enrolled squamous vs. non-squamous lung cancer patients(At 1, 2 and 3 years)
  • Patient-related outcomes Quality of Life assessment using the questionnaire for functional assessment of cancer therapy for patients with lung cancer (FACT-L version 4)(At week 9)
  • Number of participants with treatment-related adverse events as assessed by CTCAE v 4.0(With every administration)
  • Major pathologic response rate (<10% viable tumor cells)(At 12 weeks)
  • Progression-Free Survival (PFS)(At 1, 2 and 3 years)
  • Pathologic complete response rate(At 12 weeks)
  • Progression-Free Survival (PFS) in patients with 50% or more PD-L1 vs. patients with less than 50% PD-L1(At 1, 2 and 3 years)
  • Overall Survival (OS) in patients with 50% or more PD-L1 vs. patients with less than 50% PD-L1(At 1, 2 and 3 years)
  • Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria in patients with 50% or more PD-L1 vs. patients with less than 50% PD-L1(At week 9)

研究者

发起方
Arafat Tfayli
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Arafat Tfayli

Professor of Clinical Medicine

American University of Beirut Medical Center

研究点 (5)

Loading locations...

相似试验

进行中（未招募）
1 期
Clinical trial for the evaluation of a new drug (cabozantinib) treatment given before having kidney surgery in patients with kidney cancer that is advanced or has spreadocally Advanced or Metastatic Renal Cell CarcinomaMedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-001201-93-ESFundación ONCOSUR50
招募中
2 期
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCNon Small Cell Lung Cancer
NCT04875585Medical University Innsbruck33
终止
2 期
Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLCNon-small Cell Lung Cancer
NCT04926831Novartis Pharmaceuticals4
招募中
2 期
Phase II trial exploring combined neoadjuvant therapy with Pembrolizumab/Lenvatinib and adjuvant Pembrolizumab in patients with surgically resectable Non-Small- Cell Lung Cancer (NSCLC)
2024-514821-45-00Medizinische Universitaet Innsbruck33
尚未招募
2 期
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 MutationsBRAF V600 MutationMET Exon 14 MutationNSCLC
NCT06054191Sun Yat-sen University40